Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon

References

• McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, et al. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43–7.
   PubMed Web of Science ®Google Scholar
• Yardumian DA, Isenberg DA, Rustin M, Belcher G, Snaith ML, Dowd PM, et al. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220–6.
   PubMedGoogle Scholar
• Torley HI, Madhok R, Cape HA, Brouwer RM, Maddison PJ, Black CM, et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800–4.
   Google Scholar
• Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407–14.
   Google Scholar
• Martin MF, Dowd PM, Ring EF, Cooke ED, Dieppe PA, Kirby JD. Prostaglandin El infusions for vascular insuffi-ciency in progressive systemic sclerosis. Ann Rheum Dis 1981;40:350–4.
   PubMed Web of Science ®Google Scholar
• Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prosta-glandin El in Raynaud's syndrome. Ann Rheum Dis 1985;44:754–60.
   Google Scholar
• Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, et al. Treatment of Raynaud's phenomenon with intravenous prostaglandin El alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 2001;28:786–94.
   PubMed Web of Science ®Google Scholar
• Belch JJ, Newman P, Drury JK, McKenzie F, Cape11 H, Leiberman P, et al. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet 1983;1:313–5.
   Google Scholar
• Bellucci S, Kedra AW, Courmelle JM, Maclouf J, Boizard B, Dosquet-Bernard C, et al. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion. Scand J Rheumatol 1986;15:392–8.
   Google Scholar
• Musial J, Wilczynska M, Sladek K, Cierniewski CS, Nizankowski R, Szczeklik A. Fibrinolyitc activity of prosta-cyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986;31:61–70.
   PubMed Web of Science ®Google Scholar
• Bertele V, Mussoni L, Del Rosso G. Defective fibrinolytic response in atherosclerotic patients: effects of iloprost and its possible mechanism of action. Thromb Haemost 1988;60: 141–4.
   Google Scholar
• Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295–315.
   PubMed Web of Science ®Google Scholar
• Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001;81: 294–7.
   Google Scholar
• Kahaleh MB, Matucci Cerinic M, Fan P-S. Modulation of endothelial gene expression by prostanoids in systemic sclerosis. Arthritis Rheum 2000;43 (Suppl 9):5258.
   Google Scholar
• Subcommittee for Scleroderma Criteria of the American Rheumatism Association: diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). J Rheumatol 1980;23: 581–90.
   Google Scholar
• Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976;295:1149–54.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Coppola R. Von Willebrand factor. In: Jespersen J, Bertina RM, Haverkate F, editors. ECAT assays procedures. Laboratory techniques in thrombosis: a manual. Lancaster: Kluwer Academic Publishers UK, 1999. p.115.
   Google Scholar
• Rodnan GP, Lipinski E, Luksicki J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22:130–40.
   Google Scholar
• Stratton R, Shiwen X, Martin G. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241–50.
   Google Scholar
• Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud's phenomenon patients with systemic sclerosis: a double-blind randomized study. Br Med J 1989;298:561–4.
   PubMed Web of Science ®Google Scholar
• Kyle MV, Belcher G, Hazleman BL. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 1992;19:1403–6.
   Google Scholar
• Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E on human platelet function. J Lab Clin Med 1987;109:184–90.
   PubMed Web of Science ®Google Scholar
• Castagno PL, Di Molfetta L, Merlo M, Barile G, Violato F, Buzzacchino A, et al. Prospects of prostanoid therapy. Minerva Cardioangiol 2000;48:1–10.
   Google Scholar
• Rustin MHA, Kovacs IB, Cooke ED, Dowd PM, Bowcock Sa, Kirby JDT. Experience with PGE1 and PGI2 infusions in patients with systemic sclerosis and Raynaud's phenomenon. Inter Angio J 1984;3:43–7.
   Google Scholar
• Lamprecht P, Schnabel A, Gross WL. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon. Br J Rheumatol 1998;37:703–4.
   Google Scholar
• Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96:2782–4.
   Google Scholar
• Angotti C, Matucci Cerinic M, Kalfin R, Generini S, Righi A, Conforti ML, et al. Prostaglandin El (PGE1) restores the levels of vWF and ACE and modulates the circulating levels of adhesion molecules in systemic sclerosis (SSc). Arthritis Rheum ;2000:43 (Suppl 9):5261.
   Google Scholar
• Boyer-Neumann C, Brenot F, Wolf M, Peynaud-Debayle E, Duroux P, Meyer D, et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-1 in primary pulmonary hypertension. Thromb Haemostasis 1995;73: 735–6.
   Google Scholar
• Candela M, Iannino L, Pansoni A, Natalini M, Ravaglia F, Dalio L, et al. Hemocoagulative effects in patients with systemic sclerosis treated with Iloprost or Nifedipine. Eur J Clin Invest 1999;9(Suppl 1):83.
   Google Scholar
• Bachmann F, Kruithof IEKO. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 1984;10:6–17.
   PubMed Web of Science ®Google Scholar
• Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992;11:375–82.
   PubMedGoogle Scholar
• Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997;139:245–56.
   Google Scholar
• Ridker PM. Hemostatic factors and the risk of myocardial infarction. N Engl J Med 1995;333:389–90.
   PubMed Web of Science ®Google Scholar
• Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular disease. Am J Clin Pathol 1994;10:109–13.
   Web of Science ®Google Scholar
• Soma Y, Takehara K, Sato S, Ishibashi Y. Increase in plasma thrombomodulin in patients with systemic sclerosis. J Rheumatol 1993;20:1444–5.
   PubMed Web of Science ®Google Scholar
• Mercié P, Seigneur M, Conri C. Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis. J Rheumatol 1995;22:1440.
   Google Scholar
• Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, throm-boxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122–7.
   PubMed Web of Science ®Google Scholar
• Black CM, McWhirter A, Harrison NK, Kirk JM, Laurent GJ. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol 1989;28:98–103.
   Google Scholar